IL-1β, IL-1Ra and sIL-1RII in the culture supernatants of PMN and PBMC and the serum levels in patients with inflammation and patients with cancer disease of the same location

被引:9
作者
Jablonska, E
Jablonski, J
Piotrowski, L
Grabowska, Z
机构
[1] Med Acad Bialystok, Dept Immunol, PL-15230 Bialystok, Poland
[2] Med Acad Bialystok, Dept Toxicol, PL-15230 Bialystok, Poland
[3] Med Acad Bialystok, Dept Oral & Maxillofacial Surg, PL-15230 Bialystok, Poland
关键词
D O I
10.1078/0171-2985-00059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An inflammation or an other malignant process may create a microenvironment that modulates the production and activity of cytokines and their regulators. In the present study we compared the secretion of IL-1 beta and its regulatory proteins: IL-1Ra and sIL-1RII by PMN and PBMC derived from patients with inflammation and patients with cancer disease of the same location. We also examined the serum levels of these mediators in groups of patients. The results obtained revealed changes in the secretion of IL-1 beta and IL-1Ra which are more characteristic of PMN and PBMC from cancer patients than of the cells from patients with inflammation. In contrast, the secretion of sIL-1RII is more characteristic of PMN and PBMC derived from patients with inflammation. Furthermore, PMN appear to play more significant role in the secretion of IL-1Ra. into the circulation of cancer patients than PBMC. In contrast, PBMC affect to a large extent the secretion of IL-1 beta and sIL-1RII into the circulation of patients with inflammation than PMN. Concluding, the secretion of IL-1 beta and its regulatory proteins may depend on the type of immune cells and the type of the disease.
引用
收藏
页码:508 / 516
页数:9
相关论文
共 22 条
[1]  
Brown EA, 1996, CYTOKINE, V8, P828
[2]  
DEFORGE LE, 1992, AM J PATHOL, V140, P1045
[3]  
DEUREN M, 1997, BLOOD, V90, P1101
[4]   Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein [J].
Gabay, C ;
Smith, MF ;
Eidlen, D ;
Arend, WP .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (12) :2930-2940
[5]   MONOCYTE TUMOR-NECROSIS-FACTOR PRODUCTION IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA [J].
GALLO, O ;
PINTO, S ;
BOCCUZZI, S ;
DILAGHI, M ;
GALLINA, E ;
ATTANASIO, M ;
GORI, AM ;
MARTINI, F ;
ABBATE, R .
LARYNGOSCOPE, 1992, 102 (04) :447-450
[6]   Ex vivo interleukin (IL)-1β, IL-6, IL-12 and tumor necrosis factor-α responsiveness with monocytes from patients with head and neck carcinoma [J].
Heimdal, JH ;
Aarstad, HJ ;
Klementsen, B ;
Olofsson, J .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1999, 256 (05) :250-256
[7]  
Ito H, 1999, SCAND J GASTROENTERO, V34, P1139
[8]   Interleukin-1 receptor antagonists and other markers in colorectal cancer patients [J].
Iwagaki, H ;
Hizuta, A ;
Tanaka, N .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (06) :577-581
[9]  
JABLONSKA E, IN PRESS CYTOKINE
[10]  
JENKINS JK, 1994, LYMPHOKINE CYTOK RES, V13, P47